Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. (Q52758918)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 May 2017

Language	Label	Description	Also known as
English	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.	scientific article published on 8 May 2017

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

metastatic melanoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Diana Giannarelli

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Cristina Maccalli

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Wouter Hendrickx

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Riccardo Danielli

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Francesco Marincola

14

object named as

Francesco M Marincola

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

author name string

Carla Chiarucci

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Ornella Cutaia

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Gianluca Giacobini

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Giovanni Amato

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Diego Annesi

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Davide Bedognetti

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Maresa Altomonte

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Anna Maria Di Giacomo

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Giorgio Parmiani

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

publication date

8 May 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

e1323618

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Immune checkpoint inhibitors: a milestone in the treatment of melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Harnessing the immune system for the treatment of melanoma: current status and future prospects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Editorial: Combination Strategies in the Treatment of Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Immune checkpoint blockade: Releasing the brake towards hematological malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Immune Checkpoint Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

What's new in melanoma? Combination!

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

NKG2D Ligands in Tumor Immunity: Two Sides of a Coin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Immunology beats cancer: a blueprint for successful translation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

The immune microenvironment of human tumors: general significance and clinical impact

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Immune infiltration in human tumors: a prognostic factor that should not be ignored

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Immunology and immunotherapy of colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

30 June 2018

Moving beyond monotherapy in the immunotherapeutic arena: prospects for combination therapies in lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

13 August 2018

Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

13 August 2018

Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

13 August 2018

Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

13 August 2018

Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543847

13 August 2018

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1323618

21 January 2018

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1323618

21 January 2018

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1323618

21 January 2018

S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28811958

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/28811958

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28811958

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response

1 reference

https://pubmed.ncbi.nlm.nih.gov/28811958

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/2162402X.2017.1323618

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28811958%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52758918&oldid=1470299816"